Chemomab Therapeutics (CMMB) Enterprise Value (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Enterprise Value of -$10.4 million for Q4 2025, down 3.08% on a QoQ basis from -$10.1 million in Q3 2025, and down 68.64% year-over-year from -$33.0 million in Q4 2024.
Chemomab Therapeutics (CMMB) Enterprise Value (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$10.4 million for Q4 2025.
- Quarterly Enterprise Value fell 68.64% year-over-year to -$10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.4 million (down 68.64% YoY) and the FY2025 annual result came in at -$10.4 million, down 68.64% from the prior year.
- Enterprise Value was -$10.4 million for Q4 2025 at Chemomab Therapeutics, down from -$10.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.1 million in Q4 2024 and bottomed at -$66.9 million in Q2 2021.
- A 5-year average of -$29.3 million and a median of -$20.4 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value tumbled 849.59% — and 2023, when it surged 76.52%.
- Chemomab Therapeutics' Enterprise Value stood at -$15.2 million in 2021, then plunged by 162.7% to -$39.9 million in 2022, then soared by 76.52% to -$9.4 million in 2023, then soared by 34.38% to -$6.1 million in 2024, then tumbled by 68.64% to -$10.4 million in 2025.
- Business Quant data shows CMMB's Enterprise Value at -$10.4 million in Q4 2025, -$10.1 million in Q3 2025, and -$9.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Chemomab Therapeutics | 704.11 Mn | 693.75 Mn | - | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.37 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -9.51 Mn |
| Mar 31, 2025 | -10.56 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | -19.38 Mn |
| Jun 30, 2024 | -12.80 Mn |
| Mar 31, 2024 | -15.88 Mn |
| Dec 31, 2023 | -9.37 Mn |
| Sep 30, 2023 | -21.44 Mn |
| Jun 30, 2023 | -26.66 Mn |
| Mar 31, 2023 | -32.71 Mn |
| Dec 31, 2022 | -39.89 Mn |
| Sep 30, 2022 | -46.54 Mn |
| Jun 30, 2022 | -51.80 Mn |
| Mar 31, 2022 | -57.41 Mn |
| Dec 31, 2021 | -15.19 Mn |
| Sep 30, 2021 | -64.27 Mn |
| Jun 30, 2021 | -66.92 Mn |
| Mar 31, 2021 | -58.20 Mn |